Skip to main content Skip to section navigation Skip to footer
CohBar, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Programs & Pipelines
    • Overview
    • Our Approach
    • CB4211
    • CB5138 Analogs
    • Posters & White Papers
  • Patient Resources
    • Overview
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Partners
  • Careers
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Aug 28, 2020 4:05pm EDT

CohBar Announces Closing of Public Offering of Common Stock and Warrants

Aug 26, 2020 8:30am EDT

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

Aug 25, 2020 4:55pm EDT

CohBar Announces Proposed Public Offering of Common Stock and Warrants

Aug 24, 2020 9:00am EDT

CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Aug 13, 2020 4:03pm EDT

CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 05, 2020 9:00am EDT

CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference

Jul 30, 2020 9:00am EDT

CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020

Jul 07, 2020 9:00am EDT

CohBar Resumes CB4211 Phase 1b Clinical Trial

Jul 06, 2020 9:00am EDT

CohBar to Present at Sachs Novel Coronavirus Investment Forum

Jun 30, 2020 9:00am EDT

CohBar Added to Russell 2000® Index and Raises $4.4M in ATM Offering

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Page 18
  • Next Pagearrow_forward
©2023 CohBar, Inc. All Rights Reserved.
Privacy Policy Sitemap Terms of Use